USO 22074

A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma (KT-US-473-0133)

Disease Types: Cellular & Gene

Eligibility Requirements:

- Histologically-confirmed follicular lymphoma (FL) (Grade 1, 2, or 3a)

- Clinical indication for treatment.

- At least 1 measurable lesion per the Lugano Classification {Cheson 2014}

- Adequate renal, hepatic, pulmonary, and cardiac function

Available at:

• Norfolk (Brock Cancer Center)